Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer

The clinical utility of inhibiting cytochrome P450 17A1 (CYP17), a cytochrome p450 enzyme that is required for the production of androgens, has been exemplified by the approval of abiraterone for the treatment of castration-resistant prostate cancer (CRPC). Recently, however, it has been reported th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Norris, John D., Ellison, Stephanie J., Baker, Jennifer G., Stagg, David B., Wardell, Suzanne E., Park, Sunghee, Alley, Holly M., Baldi, Robert M., Yllanes, Alexander, Andreano, Kaitlyn J., Stice, James P., Lawrence, Scott A., Eisner, Joel R., Price, Douglas K., Moore, William R., Figg, William D., McDonnell, Donald P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5451248/
https://ncbi.nlm.nih.gov/pubmed/28463227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87328
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados